Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Common Equity (2021 - 2025)

PAVmed has reported Common Equity over the past 5 years, most recently at $22.3 million for Q4 2025.

  • Quarterly results put Common Equity at $22.3 million for Q4 2025, up 417.08% from a year ago — trailing twelve months through Dec 2025 was $22.3 million (up 417.08% YoY), and the annual figure for FY2025 was $22.3 million, up 417.08%.
  • Common Equity for Q4 2025 was $22.3 million at PAVmed, down from $22.5 million in the prior quarter.
  • Over the last five years, Common Equity for PAVM hit a ceiling of $79.4 million in Q4 2021 and a floor of -$24.0 million in Q4 2023.
  • Median Common Equity over the past 5 years was $22.4 million (2025), compared with a mean of $19.8 million.
  • Biggest five-year swings in Common Equity: crashed 2146.02% in 2024 and later surged 417.08% in 2025.
  • PAVmed's Common Equity stood at $79.4 million in 2021, then crashed by 86.23% to $10.9 million in 2022, then plummeted by 319.66% to -$24.0 million in 2023, then soared by 70.72% to -$7.0 million in 2024, then surged by 417.08% to $22.3 million in 2025.
  • The last three reported values for Common Equity were $22.3 million (Q4 2025), $22.5 million (Q3 2025), and $28.2 million (Q2 2025) per Business Quant data.